Veritas In Silico Inc.(130A) News

Veritas In Silico, First Half Net Income Loss Widens, Apr-Jun Net Income Loss Widens

Financial Briefing Materials - FY2026 Second Quarter

Non-consolidated Financial Results for the Six Months Ended June 30, 2026 [Under Japanese GAAP]

Veritas In Silico surges in afternoon session after filing joint patent with Mitsubishi Gas Chemical Company,Inc. <4182>

Joint Patent Application Filed for lncRNA-Targeting Drugs

Personnel Changes in Executive Officer

Pre-Consultation Meeting with Pharmaceuticals and Medical Devices Agency (PMDA) towards the Commercialization of the Drug Delivery System "Perfusio"

SpiroChem and Veritas In Silico entered into Joint Research Agreement to Initiate the Discovery of Next Generation mRNA Binding Chemical Matter

Non-consolidated Financial Results for the Three Months Ended March 31,2026 [Under Japanese GAAP]

Notice of Extraordinary Loss Due to Impairment Accounting

Financial Results - FY2026 First Quarter

Veritas In Silico, Jan-Mar (1Q) Net Income Loss Widens

Announcement of the Publication of a Research Article on AISLAR, a Method for Streamlining Screening That Supports Our AI-Driven Drug Discovery

Veritas In Silico tumbles for first time in 3 sessions after ending joint drug discovery research with Takeda◇

Termination of Collaborative Drug Discovery Research with Takeda on mRNA-Targeted Small-Molecule Drugs

Appointing Candidates for Directors, Auditor, and Alternate Audit & Supervisory Board Member

Veritas In Silico, The Current Fiscal Year's Net Income to Widen

Summary of Non-consolidated Financial Results for the Fiscal Year ended December 31, 2025 [Under Japanese GAAP]

Company Presentation

Financial Results - Fiscal Year Ended December 31, 2025